Hepatopulmonary syndrome future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{Soroush}} | {{CMG}}; {{AE}} {{Soroush}} | ||
==Overview== | ==Overview== | ||
Norfloxacin, pentoxifylline, inhaled N(G)-nitro-L-arginine methyl ester, nitric oxide inhalation and methylene blue injection, are among suggested and studied medical treatments for HPS. | |||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
* | *Norfloxacin, pentoxifylline, inhaled N(G)-nitro-L-arginine methyl ester, nitric oxide inhalation and methylene blue injection, are among suggested and studied medical treatments for HPS. Non of them yet approved as standard treatment for HPS. | ||
<ref name="pmid20816858">Gupta S, Faughnan ME, Lilly L, Hutchison S, Fowler R, Bayoumi AM (2010) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=20816858 Norfloxacin therapy for hepatopulmonary syndrome: a pilot randomized controlled trial.] ''Clin Gastroenterol Hepatol'' 8 (12):1095-8. [http://dx.doi.org/10.1016/j.cgh.2010.08.011 DOI:10.1016/j.cgh.2010.08.011] PMID: [https://pubmed.gov/20816858 20816858]</ref> | <ref name="pmid20816858">Gupta S, Faughnan ME, Lilly L, Hutchison S, Fowler R, Bayoumi AM (2010) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=20816858 Norfloxacin therapy for hepatopulmonary syndrome: a pilot randomized controlled trial.] ''Clin Gastroenterol Hepatol'' 8 (12):1095-8. [http://dx.doi.org/10.1016/j.cgh.2010.08.011 DOI:10.1016/j.cgh.2010.08.011] PMID: [https://pubmed.gov/20816858 20816858]</ref> | ||
<ref name="pmid18779471">Gupta LB, Kumar A, Jaiswal AK, Yusuf J, Mehta V, Tyagi S et al. (2008) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=18779471 Pentoxifylline therapy for hepatopulmonary syndrome: a pilot study.] ''Arch Intern Med'' 168 (16):1820-3. [http://dx.doi.org/10.1001/archinte.168.16.1820 DOI:10.1001/archinte.168.16.1820] PMID: [https://pubmed.gov/18779471 18779471]</ref> | <ref name="pmid18779471">Gupta LB, Kumar A, Jaiswal AK, Yusuf J, Mehta V, Tyagi S et al. (2008) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=18779471 Pentoxifylline therapy for hepatopulmonary syndrome: a pilot study.] ''Arch Intern Med'' 168 (16):1820-3. [http://dx.doi.org/10.1001/archinte.168.16.1820 DOI:10.1001/archinte.168.16.1820] PMID: [https://pubmed.gov/18779471 18779471]</ref> | ||
Revision as of 15:11, 5 September 2019
|
Hepatopulmonary syndrome Microchapters |
|
Differentiating Hepatopulmonary syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hepatopulmonary syndrome future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Hepatopulmonary syndrome future or investigational therapies |
|
FDA on Hepatopulmonary syndrome future or investigational therapies |
|
CDC on Hepatopulmonary syndrome future or investigational therapies |
|
Hepatopulmonary syndrome future or investigational therapies in the news |
|
Blogs on Hepatopulmonary syndrome future or investigational therapies |
|
Risk calculators and risk factors for Hepatopulmonary syndrome future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]
Overview
Norfloxacin, pentoxifylline, inhaled N(G)-nitro-L-arginine methyl ester, nitric oxide inhalation and methylene blue injection, are among suggested and studied medical treatments for HPS.
Future or Investigational Therapies
- Norfloxacin, pentoxifylline, inhaled N(G)-nitro-L-arginine methyl ester, nitric oxide inhalation and methylene blue injection, are among suggested and studied medical treatments for HPS. Non of them yet approved as standard treatment for HPS.
References
- ↑ Gupta S, Faughnan ME, Lilly L, Hutchison S, Fowler R, Bayoumi AM (2010) Norfloxacin therapy for hepatopulmonary syndrome: a pilot randomized controlled trial. Clin Gastroenterol Hepatol 8 (12):1095-8. DOI:10.1016/j.cgh.2010.08.011 PMID: 20816858
- ↑ Gupta LB, Kumar A, Jaiswal AK, Yusuf J, Mehta V, Tyagi S et al. (2008) Pentoxifylline therapy for hepatopulmonary syndrome: a pilot study. Arch Intern Med 168 (16):1820-3. DOI:10.1001/archinte.168.16.1820 PMID: 18779471
- ↑ Tanikella R, Philips GM, Faulk DK, Kawut SM, Fallon MB (2008) Pilot study of pentoxifylline in hepatopulmonary syndrome. Liver Transpl 14 (8):1199-203. DOI:10.1002/lt.21482 PMID: 18668653
- ↑ Brussino L, Bucca C, Morello M, Scappaticci E, Mauro M, Rolla G (2003) Effect on dyspnoea and hypoxaemia of inhaled N(G)-nitro-L-arginine methyl ester in hepatopulmonary syndrome. Lancet 362 (9377):43-4. DOI:10.1016/S0140-6736(03)13807-X PMID: 12853200
- ↑ Schenk P, Madl C, Rezaie-Majd S, Lehr S, Müller C (2000) Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med 133 (9):701-6. DOI:10.7326/0003-4819-133-9-200011070-00012 PMID: 11074903
- ↑ Jounieaux V, Leleu O, Mayeux I (2001) Cardiopulmonary effects of nitric oxide inhalation and methylene blue injection in hepatopulmonary syndrome. Intensive Care Med 27 (6):1103-4. PMID: 11497151